These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Ozieranski P; Saito H; Rickard E; Mulinari S; Ozaki A Global Health; 2023 Mar; 19(1):14. PubMed ID: 36869318 [TBL] [Abstract][Full Text] [Related]
23. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. Yamamoto K; Murayama A; Ozaki A; Saito H; Sawano T; Tanimoto T Int Urogynecol J; 2021 Feb; 32(2):443-451. PubMed ID: 33151353 [TBL] [Abstract][Full Text] [Related]
24. The trends in EMR and CPOE adoption in Japan under the national strategy. Yoshida Y; Imai T; Ohe K Int J Med Inform; 2013 Oct; 82(10):1004-11. PubMed ID: 23932755 [TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
26. Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan. Murayama A; Senoo Y BMC Med Ethics; 2024 Feb; 25(1):22. PubMed ID: 38378633 [TBL] [Abstract][Full Text] [Related]
27. [How to Understand "Clinical Ethics" and "Research Ethics" in Clinical Settings--Incorporation of IRB, REC, and CEC in Hospital Organizations]. Ita K Rinsho Byori; 2016 Feb; 64(2):204-10. PubMed ID: 27311285 [TBL] [Abstract][Full Text] [Related]
28. Biobanking of human biological material and the principle of noncommercialisation of the human body and its parts. Pawlikowska J; Pawlikowski J; Krekora-Zając D Bioethics; 2023 Feb; 37(2):154-164. PubMed ID: 36510765 [TBL] [Abstract][Full Text] [Related]
29. Support for recognition and payment options for egg and sperm donation in New Zealand and Australia. Goedeke S; Shepherd D; Rodino IS Hum Reprod; 2020 Jan; 35(1):117-129. PubMed ID: 31967308 [TBL] [Abstract][Full Text] [Related]
30. Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation. Nissanholtz-Gannot R; Yankellevich A Isr J Health Policy Res; 2017 Sep; 6(1):45. PubMed ID: 28946915 [TBL] [Abstract][Full Text] [Related]
31. Toward the realization of a better aged society: messages from gerontology and geriatrics. Arai H; Ouchi Y; Yokode M; Ito H; Uematsu H; Eto F; Oshima S; Ota K; Saito Y; Sasaki H; Tsubota K; Fukuyama H; Honda Y; Iguchi A; Toba K; Hosoi T; Kita T; Geriatr Gerontol Int; 2012 Jan; 12(1):16-22. PubMed ID: 22188494 [TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Luiza VL; Chaves LA; Silva RM; Emmerick IC; Chaves GC; Fonseca de Araújo SC; Moraes EL; Oxman AD Cochrane Database Syst Rev; 2015 May; 2015(5):CD007017. PubMed ID: 25966337 [TBL] [Abstract][Full Text] [Related]
33. Regulation of Stem Cell Technology in Malaysia: Current Status and Recommendations. Gopalan N; Nor SNM; Mohamed MS Sci Eng Ethics; 2020 Feb; 26(1):1-25. PubMed ID: 31123979 [TBL] [Abstract][Full Text] [Related]
34. [Stem cell research and science and technology policy in Japan]. Yashiro Y Nihon Rinsho; 2011 Dec; 69(12):2251-6. PubMed ID: 22242329 [TBL] [Abstract][Full Text] [Related]
35. Necessity of cooperation with government on publication of scientific research results for intractable diseases. Inagaki Y; Song P Intractable Rare Dis Res; 2013 May; 2(2):69-71. PubMed ID: 25343106 [TBL] [Abstract][Full Text] [Related]
36. International Society for Stem Cell Research (ISSCR) Guidelines for the Conduct of Human Embryonic Stem Cell Research (December 2006). Dickens BM Med Law; 2008 Mar; 27(1):179-90. PubMed ID: 18592890 [TBL] [Abstract][Full Text] [Related]
37. [The limits of a principlist approach in the ethics of donation of elements and products of the human body. About some examples]. Thibert JB Transfus Clin Biol; 2020 Aug; 27(3):191-199. PubMed ID: 32621906 [TBL] [Abstract][Full Text] [Related]
38. Evaluating Industry Payments Among Dermatology Clinical Practice Guidelines Authors. Checketts JX; Sims MT; Vassar M JAMA Dermatol; 2017 Dec; 153(12):1229-1235. PubMed ID: 29049553 [TBL] [Abstract][Full Text] [Related]
39. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019. Murayama A; Kamamoto S; Kawashima M; Saito H; Yamashita E; Tanimoto T; Ozaki A BMJ Open; 2023 Apr; 13(4):e068237. PubMed ID: 37072354 [TBL] [Abstract][Full Text] [Related]
40. Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study. Raftery J; Bryant J; Powell J; Kerr C; Hawker S Health Technol Assess; 2008 Apr; 12(10):1-128, iii. PubMed ID: 18405468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]